EFM
CATX icon

E Fund Management’s Perspective Therapeutics CATX Stock Holding History

E Fund Management’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53.9K Buy
15,820
+4,153
+36% +$15.7K ﹤0.01% 485
2026
Q1 		$48.7K Buy
+11,667
New +$49.3K ﹤0.01% 489

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

E Fund Management's CATX Position: Q2 2026 in Review

E Fund Management increased its Perspective Therapeutics (CATX) stake by 36% in Q2 2026, buying an estimated $15.7K and bringing the position to 15,820 shares worth $53.9K. The position accounts for ﹤0.01% of the portfolio, ranked #485.

E Fund Management first reported a position in CATX in Q1 2026 and has held it in 2 quarters since. 132 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • E Fund Management held 15,820 shares of Perspective Therapeutics worth $53.9K as of Q2 2026.
  • E Fund Management bought 4,153 Perspective Therapeutics shares in Q2 2026, an estimated $15.7K.
  • Perspective Therapeutics made up ﹤0.01% of E Fund Management's portfolio in Q2 2026, its #485 holding.
  • E Fund Management first reported a position in Perspective Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 132 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.